Dr Reddy's Q1 FY27 Net Profit Declines 69% Amid Revenue Drop and Semaglutide Provisions
Dr Reddy's Laboratories reported a significant 69% year-on-year decline in consolidated net profit to around Rs 443 crore for the quarter ended June 2026, primarily due to Rs 239 crore provisions related to semaglutide inventory costs. Consolidated revenues fell about 5.5-6% to approximately Rs 8,070 crore. The North American market saw notable revenue declines amid pricing pressures, while segments like Pharmaceutical Services and Active Ingredients showed modest growth. Sequentially, profits and revenues improved compared to the previous quarter, reflecting operational resilience amid market challenges.
First-hand measurement across 6 sources
We measured how 6 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (44/100). Lens Score 36/100.
Outlets measured: businessstandard, news18, businessstandard, freepressjournal, thefinancialexpress, republicworld. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (35–50/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
republicworld broke this story on 22 Jul, 11:21 am. Other outlets followed.